Resistência bacteriana à azitromicina: causas, efeitos e combate ao COVID-19

Autor: Silva Segundo, Raylton Jansen e, Rufino, Júlia Passos, Sousa, Lunalva Gabrielli Veras, Rodrigues, Anna Eduarda Linhares, Falcão, Anna Lira Soares, Lima, Isabelle Carvalho de Melo, Cavalcanti , Lívia Ayres de Miranda, Dias, Ana Carolina Soares, Oliveira Filho, José Williams Gomes de

Publikováno v: Research, Society and Development; Vol. 11 No. 6; e27711629198
Research, Society and Development; Vol. 11 Núm. 6; e27711629198
Research, Society and Development; v. 11 n. 6; e27711629198
Research, Society and Development
Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI

Introduction: azithromycin was one of the most employed medications during the beginning of the SARS-CoV2 pandemic, despite the lack of scientific basis for its use treatment of COVID-19. Its uncontrolled adoption has risen as a public health problem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::d050d501f5bface0223ab8db9ba6b20e
https://rsdjournal.org/index.php/rsd/article/view/29198